EUROPEAN ASSOCIATION OF HAEMOPHILIA AND ALLIED D..
17th annual EAHAD Congress6 - 9 February 2024 Frankfurt
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| 1-PT | Using evidence-based co-design to develop a hydrid based exercise intervention that aims to increase confidence to exercise in persons with haemophilia | Stephanie Taylor |  Received |
 |
|||
| 3-PT | The DASH Project - DEVELOPING AHP SERVICES FOR PEOPLE WITH HAEMOPHLIA | Fionnuala Sayers | Received |
|
|||
| 4-PO | A single centre assessment of the frequency and clinical relevance of discrepant factor VIII assays both in persons without a disorder of haemostasis and in those with haemophilia A | David Allsup | Received |
|
|||
| 8-PO | Challenges in determining the severity of hemophilia A: an insight in discrepancies between factor VIII assays | Marie-Astrid van Dievoet | Received |
|
|||
| 14-PO | FVIII post infusion monitoring surveys: Results and analysis from the updated UK NEQAS BC Haemophilia programmes 2023. | Anna Williams | Received |
|
|||
| 15-PO | Association of Thrombin activatable fibrinolysis inhibitor (TAFI) with the severity of haemophilia B | Josipa Pavi&263; | Received |
|
|||
| 21-PO | Investigation of the suitability of the ROTEM assay to measure coagulation potential in blood from patients on concizumab prophylaxis | Judit Meszaros | Received |
|
|||
| 31-PO | Cardiovascular safety and brain protective effect of emicizumab in patients with hemophila older than 40 | Cedric Hermans | Received |
|
|||
| 32-PO | A Novel Gene Editing Lexicon Strategy for the Haemophilia Community | Annie Popova | Received |
|
|||
| 36-PO | A case of acquired factor XI deficiency and retroperitoneal bleed associated with Streptococcus pyogenes cellulitis | Timea Szanto | Received |
|
|||
| 41-PO | Personalised prophylaxis with simoctocog alfa versus standard prophylaxis with efanesoctocog alfa in haemophilia A, a matching-adjusted indirect comparison | Gillian Patman | Received |
|
|||
| 42-PO | Personalised prophylaxis with simoctocog alfa versus standard emicizumab prophylaxis in haemophilia A, a matching-adjusted indirect comparison | Gillian Patman | Received |
|
|||
| 43-PO | Interim Analysis of Real-World Effectiveness and Usage of Recombinant Factor IX Fc for Surgical Haemostasis from the 24-Month Prospective, Non-Interventional B-MORE Study | Sana Yaar | Received |
|
|||
| 44-PO | International Data Integration Program of the WFH World Bleeding Disorders Registry: bringing Europe data to the global stage | Donna Coffin | Received |
|
|||
| 47-PO | Treatment-related Humanistic Unmet Needs in Haemophilia B Without Inhibitors | Brooke Morriswood | Received |
|
|||
| 50-PO | Clinical overview of perioperative outcomes from the XTEND-Kids study | Hannah Nelson | Received |
|
|||
| 61-PO | Varna Expert center of coagulopathies and rare anemias 10 years experience | Elina Peteva | Received |
|
|||
| 62-PO | Promoting Gender Equity in Hemophilia Care through Proactive and Systematic Screening of Hemophilia Carriers: Results of the PROCARRIERS1 study | Evelien Krumb | Received |
|
|||
| 64-PO | Surgical Procedures and Hemostatic Outcome in Patients with Hemophilia Receiving Concizumab Prophylaxis During the Phase 3 explorer7 and explorer8 Trials | Judit Meszaros | Received |
|
|||
| 67-PO | Novel insights into Factor VIII and FIX levels among pediatric hemophilia carriers | Luke Hayden | Received |
|
|||
| 68-PO | Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Secondary Paediatric Analysis from the 24-Month French, Prospective, Non-Interventional B-SURE Study | Yasha Najafi | Received |
|
|||
| 79-PO | Patient preferences and usage patterns of mobile device applications for haemophilia A prophylaxis in Eastern Europe: results from a descriptive, observational, cross-sectional, survey-based study | Laszlo Nemes | Received |
|
|||
| 82-PO | Emerging and exciting new treatments in hemophilia future | Luis Miguel Moura | Received |
|
|||
| 85-PO | Real-world effectiveness and safety of a recombinant Factor VIII Fc in patients with haemophilia A by age groups: Pooled analysis (A-SURE/PREVENT) | Liz Beatty | Received |
|
|||
| 88-PO | Trial in Progress: Disease Characteristics of Hemophilia B in Patients Receiving Standard-of-Care Prophylactic Factor IX (FIX) Replacement Therapy (HONEY-B) | Annie Popova | Received |
|
|||
| 90-PO | Emicizumab as a primary and immediate standalone therapy for acquired hemophilia A: shaping a novel therapeutic approach for a complex hematological condition | Morgane Thiry | Received |
|
|||
| 94-PO | Safety, efficacy, and laboratory profile of reduced Emicizumab dosing in hemophilia A patients | Timea Szanto | Received |
|
|||
| 96-PO | Observational, PRO study to Evaluate Quality of Life for Hemophilia patients on Hemlibra, Single study | Ohoud Kashari | Received |
|
|||
| 97-PO | Using of Emicizumab in Pediatric Hemophilia a Patients: KSA Single Center Experience | ohoud kashari | Received |
|
|||
| 99-PO | Real-world effectiveness and safety of a recombinant Factor VIII Fc in patients with haemophilia A by disease severity: Pooled analysis (A-SURE/PREVENT) | Liz Beatty | Received |
|
|||
| 100-PO | The value-based healthcare approach to haemophilia: development of outcome measures for the evaluation of care of people with haemophilia. | Paolo Angelo Cortesi | Received |
|
|||
| 103-PO | Immune Tolerance Induction with a Recombinant Factor VIII Fc in Haemophilia A: Final Data from a Chart Review Study | Yasha Najafi | Received |
|
|||
| 107-PO | Enhancing haemophilia assessment and monitoring with novel digital biomarkers using HemoCopilot: a digital self-assessment solution for People with Haemophilia | Sébastien Lobet | Received |
|
|||
| 108-PO | ACTIVLIM-Hemo, a new valid, reliable, unidimensional and linear measure of activity limitations in hemophilia | Sebastien Lobet | Received |
|
|||
| 113-PO | Efanesoctocog Alfa Prophylaxis Outcomes in European Patients From the XTEND-1 Trial | Yasha Najafi | Received |
|
|||
| 118-PO | Reducing potential data gap after Gene Therapy using myGTR a patient engagement tool from World Federation of Hemophilia Gene Therapy Registry | Toong Youttananukorn | Received |
|
|||
| 120-PO | Impacts on Functional Outcomes Following Total Knee Arthroplasty in Hemophilia Patients: A Comparative Study of Pain Catastrophizing and Adaptation to Artificial Joints | Ufuk Gürsoy Kanlikaya | Received |
|
|||
| 121-PO | Real-life single center experience on the effectiveness of Emicizumab prophylaxis in patients with Haemophilia A with and without inhibitors associated with improvement of health-related quality of life. | Uros Markovic | Received |
|
|||
| 124-PO | Seven-year follow-up of valoctocogene roxaparvovec gene therapy for haemophilia A | Emily Williams | Received |
|
|||
| 126-PO | Emicizumab Prophylaxis in People with Haemophilia A: Summary of 10 Years of Safety Data on Thromboembolic Events and Thrombotic Microangiopathy | Helen Miller | Received |
|
|||
| 127-PO | Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Interim Analysis in Paediatric Patients from the 24-Month, Prospective, Non-Interventional B-MORE Study | Sana Yaar | Received |
|
|||
| 128-PO | The efficacy, safety, and pharmacokinetics of N8-GP in previously treated Chinese patients with haemophilia A: results from the phase 3b pathfinder10 study | Jessie Arries | Received |
|
|||
| 129-PO | Comparing inhibitor development in (plasma derived vs recombinant) FVIII/FIX concentrates in severe haemophilia: reporting on 1392 PUPs from EUHASS and Canadian registries | Kathelijn Fischer | Received |
|
|||
| 130-PO | Uptake of emicizumab in PUPs with severe haemophilia A and changes in inhibitor incidence | Kathelijn Fischer | Received |
|
|||
| 144-PO | Health-related quality of life and long-term joint damage in people with severe Haemophilia A in Brazil | Jonathan Evans | Received |
|
|||
| 150-PO | ACQUIRED HAEMOPHILIA - CLINICAL MANIFESTATIONS AND MANAGEMENT; A SINGLE CENTRE EXPERIENCE | Anna Kouramba | Received |
|
|||
| 158-PO | Experience of Treatment in Children with Severe Hemophilia B in a single center | Carmen Gil Barroso | Received |
|
|||
| 162-PO | Characteristics of Girls with haemophilia A or B included in the PedNet registry | Marloes de Kovel | Received |
|
|||
| 163-PO | Gathering and Disseminating Standardized Gene Therapy Data The World Federation of Hemophilia Gene Therapy Registry | Mayss Naccache | Received |
|
|||
| 164-PO | The World Federation of Hemophilia Living Guidelines Model | Mona Mayla | Received |
|
|||
| 166-PO | Psychometric evaluation of the Haem-A-QoL in adults with haemophilia B | Sheena Thakkar | Received |
|
|||
| 167-PO | The Haemophilia Activities List: psychometric evaluation in adults with haemophilia B | Sheena Thakkar | Received |
|
|||
| 194-PO | Managing von Willebrand disease with inhibitors during prophylaxis with a plasma derived von Willebrand Factor/Factor VIII concentrate The WIL-31 study | Gillian Patman | Received |
|
|||
| 197-PO | Cost model of long-term prophylaxis with von Willebrand Factor concentrate | Antonio Palomero | Received |
|
|||
| 202-PO | A case report of type-2B Von Willebrand Disease and gastrointestinal bleeding | María Nieves Alonso Escobar | Received |
|
|||
| 206-PO | RECOMBINANT VON WILLEBRAND FACTOR TREATMENT OUTCOMES IN UK ADULTS WITH VON WILLEBRAND DISEASE: A RETROSPECTIVE CHART REVIEW STUDY | Ollie Heard | Received |
|
|||
| 210-PO | Efficacy and Safety of Plasma-derived VWF Concentrates in a cohort of 93 Patients with Type 3 von Willebrand Disease enrolled in 3WINTERS-IPS: Results of the 2-year Prospective Clinical Observation | Augusto Federici | Received |
|
|||
| 213-PO | Accumulation of Factor VIII and von Willebrand Factor during prophylaxis with a Plasma-derived von Willebrand Factor/Factor VIII Concentrate during the WIL-31 Study | Gillian Patman | Received |
|
|||
| 241-PO | Prospective Examination of Acquired von Willebrand Syndrome Co-occurrence in Patients with BCR-ABL1-negative Myeloproliferative Neoplasms. | Mohamed Hussam Aswad | Received |
|
|||
| 259-PO | No added value of testing for factor XIII and a2-antiplasmin deficiency in patients with a mucocutaneous bleeding disorder of unknown cause | Sander Ariëns | Received |
|
|||
| 261-PO | Experience in the Treatment of ITP with Fostamatinib | Pilar Pérez García | Received |
|
|||
| 266-PO | Participation in sports in Dutch children and adults with inherited platelet function disorders is similar to the general population: not afraid to participate. | Annick de Moor | Received |
|
|||
| 269-PO | IMPLEMENTATION OF SINGLE FACTOR X REPLACEMENT TREATMENT IN ADULTS WITH INHERITED SEVERE FACTOR X DEFICIENCY | Halin Veronicka Buruno | Received |
|
|||
| 278-PO | Initiatives of the EAHAD Glanzmann Working Group | Roger Schutgens | Received |
|
|||
| 290-PO | Comparison of outcome assessment in prophylaxis versus on demand treatment: A research support program of WFH World Bleeding Disorders Registry | Dinkar Viswam | Received |
|
|||
| 298-PO | Health-related quality of life (HRQoL) in Greek patients with von Willebrand Disease (VWD) | Ioannis Vasilopoulos | Received |
|
|||
| 310-PO | A New Tool to Assist in Treatment Selection The World Federation of Hemophilia (WFH) Shared Decision-Making (SDM) Tool | Donna Coffin | Received |
|
|||
| 312-PO | Intergenerational Impact of the Contaminated Blood Scandal | Sally-Anne Wherry | Received |
|
|||
17th annual EAHAD Congress
6 - 9 February 2024 Frankfurt
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 06/02/2024 TO 06/02/2024
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
